Pharma Gets Reprieve From ‘Worst-Case Scenario,’ But Trump Is Still A Question Mark
The pharmaceutical industry was braced for a possible Democratic takeover. But Donald Trump might not be an ally. Meanwhile, pharmaceutical stocks are up on the news of his win.
Big Pharma's Big Question: Is Trump Friend Or Foe?
Should President Donald Trump make drug makers relieved? Or anxious? They’re not sure. (Scott, 11/9)
The Wall Street Journal:
Health-Care Stocks Emerge As Winners From Trump Vote
Health-care companies have emerged as the main gainers from Donald Trump’s win in the U.S. presidential election, despite a broad stock market selloff across the world. The U.S. premarket pointed to a 2% opening loss for the S&P 500 during early European trade, but futures on pharmaceuticals showed sharp rises, led by Endo International PLC, Mylan NV and Perrigo Co. PLC. The Stoxx Europe 600 index was down 0.5%, but the health-care and mining sectors notched 3.5% and 3% gains respectively. All other sectors were in the red. (Sindreu and Iosebashvili, 11/9)